User:Justin Reggi/sandbox

Flexion Therapeutics, Inc.
	File:None
Company type	Private
Industry	Biotechnology
Headquarters	Woburn, MA
Website	[1]

This is the user sandbox of Justin Reggi. A user sandbox is a subpage of the user's user page. It serves as a testing spot and page development space for the user and is not an encyclopedia article. Create or edit your own sandbox here.

Other sandboxes: Main sandbox | Template sandbox

Finished writing a draft article? Are you ready to request review of it by an experienced editor for possible inclusion in Wikipedia? Submit your draft for review!

Flexion Therapeutics, Inc. is a Woburn, MA - based company that is developing long-lasting, joint-injection (intra-articular injection) therapies for the treatment of osteoarthritis. ^[1] ^[2] Flexion’s pipeline consists of three novel drug candidates (FX005, FX006, FX007) for the treatment of pain associated with mild, moderate, and severe osteoarthritis. ^[3] FX005 is a sustained release, intra-articular p38 Mitogen Activated Protein Kinase (p38 MAP) inhibitor, FX006 is a sustained release, intra-articular steroid, and FX007 is a sustained release, intra-articular TrkA receptor antagonist. ^[4] ^[5]

References[edit]

^ Gormley, Brian. (28 November 2011). "Flexion Changes Endgame, Advances Osteoarthritis Drugs." Dow Jones VentureWire.
^ Young, Robin.(8 March 2012)."Could This Be Orthopedics’ Future?" Orthopedics This Week.
^ Jackson, Mandy.(30 May 2012)."Flexion Phase II Data for FX005 gives Clinical PoC in Arthritis Pain." SCRIP.
^ Weintraub, Arlene. (30 May 2012). "Flexion Overhaul Bears Fruit With Upbeat Data From Arthritis Trial." XConomy.
^ Gormley, Brian. (28 November 2011). "Flexion Therapeutics Raises 13M from insiders, Progresses Pipeline." Dow Jones VentureWire.

External links[edit]

Flexion Therapeutics, Inc. website

Category:Biotechnology companies

[1] Gormley, Brian. (28 November 2011). "Flexion Changes Endgame, Advances Osteoarthritis Drugs." Dow Jones VentureWire.

[2] Young, Robin.(8 March 2012)."Could This Be Orthopedics’ Future?" Orthopedics This Week.

[3] Jackson, Mandy.(30 May 2012)."Flexion Phase II Data for FX005 gives Clinical PoC in Arthritis Pain." SCRIP.

[4] Weintraub, Arlene. (30 May 2012). "Flexion Overhaul Bears Fruit With Upbeat Data From Arthritis Trial." XConomy.

[5] Gormley, Brian. (28 November 2011). "Flexion Therapeutics Raises 13M from insiders, Progresses Pipeline." Dow Jones VentureWire.

[1]

[2]

[3]

[4]

[5]